Ketalar (Ketamine)

Ketamine works by blocking NMDA receptors in the brain, which reduces excitatory neurotransmission and disrupts pain signal processing. This antagonism produces a dissociative state, providing both anesthesia and analgesia. Additional actions at opioid receptors, monoamine transporters, and voltage‑gated calcium channels further contribute to its analgesic and psychomimetic effects.

The appropriate dose of Ketalar is determined by the prescribing clinician based on the patient’s age, weight, medical condition, and the intended procedure. Dosing regimens are individualized and may be adjusted during the procedure to maintain the desired level of anesthesia or sedation. Healthcare providers follow local guidelines and product labeling when calculating the dose.

Safety data for ketamine use during pregnancy and lactation are limited, and the drug is generally classified as a precautionary agent. It should only be used when the potential benefit justifies any potential risk to the fetus or infant. Breastfeeding mothers should consult their healthcare provider, as ketamine can be excreted in breast milk.

To order Ketalar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After validation, the team provides pricing, availability, shipping details—including any cold‑chain requirements—and assists with import documentation.

Ketalar differs from traditional inhalational or opioid‑based anesthetics by providing dissociative anesthesia through NMDA receptor blockade rather than GABA‑mediated sedation. It offers rapid onset, maintains cardiovascular stability in many patients, and preserves airway reflexes better than some agents. However, it can produce psychomimetic side effects and requires careful monitoring, especially in patients with psychiatric histories.

Ketalar must be stored at 2‑8 °C in a refrigerator, protected from light, and should never be frozen or shaken. The vial should remain in its original packaging until use to maintain sterility. If the product reaches room temperature, it may be used for a limited period as indicated in the manufacturer’s instructions, but should be returned to refrigeration promptly.

Ketalar is administered by a trained healthcare professional via intramuscular or intravenous injection. The route, rate of injection, and total dose are selected based on the clinical situation, such as induction of anesthesia, maintenance during surgery, or procedural sedation. Continuous monitoring of vital signs is required throughout administration.

Serious risks include respiratory depression, severe hypertension, cardiac arrhythmias, emergence delirium or vivid hallucinations during recovery, and rare allergic reactions. Prompt recognition and management of these events are essential, and resuscitation equipment should be readily available whenever Ketalar is used.

Ketalar is contraindicated in patients with known hypersensitivity to ketamine or any formulation component. Caution is advised in individuals with uncontrolled hypertension, severe cardiovascular disease, elevated intracranial pressure, or a history of psychosis. Pediatric use should follow specific guidelines, and the drug should be avoided in patients where a non‑dissociative anesthetic is preferred.